Ozempic for drinking: what the new GLP-1 + CBT trial actually means for alcohol use disorder

Alcohol kills roughly 105,000 Americans a year — close to the count for drug overdoses — and the medications we have for alcohol use disorder are good, but not great. Naltrexone, acamprosate, and disulfiram all work for some people; their typical “number needed to treat” sits at seven or higher, meaning you have to treat seven people to see one durable benefit. So when a randomized trial reports a number-needed-to-treat of 4.3, the field pays attention.

That’s the headline from a new NIH-backed trial announced in April 2026. Researchers added weekly semaglutide — the same active ingredient as Ozempic and Wegovy — to standard cognitive behavioral therapy for adults with alcohol use disorder and comorbid obesity. After 26 weeks, the semaglutide group had a 41.1% reduction in heavy drinking days, a 13.7 percentage-point greater reduction than the placebo-plus-CBT group.

This is the second positive randomized trial of GLP-1 medications for alcohol use disorder in 18 months — building on the 2025 JAMA Psychiatry paper that first showed the signal in a smaller laboratory setting. The picture is consistent: GLP-1 medications appear to reduce craving and heavy drinking days. The picture is also incomplete. Here is what we actually know, what we don’t, and what to do with the news.

What the trial showed

The study enrolled 108 treatment-seeking adults with alcohol use disorder and comorbid obesity. Everyone got cognitive behavioral therapy. Half got weekly semaglutide; half got placebo. After 26 weeks:

• Heavy drinking days dropped 41.1% in the semaglutide group, versus 27.4% in placebo.
• The number needed to treat was 4.3 — meaning roughly one in four people benefited durably. Approved medications for alcohol use disorder typically require seven or more treated patients to produce one similar benefit.
• Cravings were lower in the semaglutide group across multiple validated measures.

The April 2026 paper extends an earlier smaller trial published in JAMA Psychiatry in early 2025, which found that low-dose semaglutide reduced drinks-per-drinking-day and weekly cravings during a posttreatment laboratory drinking session. The new trial is larger, longer, real-world, and pairs the medication with the standard psychosocial care most clinicians already offer.

A separate systematic review and meta-analysis of 14 GLP-1 studies — four randomized, ten observational — found consistent reductions in AUDIT scores, drinking days, and craving. Phase 3 trials specifically for alcohol use disorder are now underway.

Why might GLP-1s reduce drinking?

GLP-1 receptor agonists activate receptors in brain regions involved in reward processing — including the ventral tegmental area and nucleus accumbens — not just the gut. Animal studies have shown for over a decade that GLP-1 activation reduces alcohol self-administration. The mechanism is still being mapped, but the leading hypothesis is that GLP-1 dampens the dopaminergic response to rewarding stimuli, which includes both food and ethanol. That’s the same biology that makes these drugs effective for weight loss; the appetite-and-craving system isn’t separated by substrate.

Notably, this isn’t unique to alcohol. Smaller signals exist for nicotine, opioids, and stimulants — though the alcohol evidence is the strongest.

What this trial is not

A few important caveats.

The trial population was adults with both alcohol use disorder and obesity. That is a meaningful clinical population, and likely a population already eligible for semaglutide on a body-composition indication. But it’s not the same as “adults with alcohol use disorder, full stop.” The medication’s effect in normal-BMI patients with AUD is still being studied.

This is not an FDA-approved indication for alcohol use disorder. Semaglutide is approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Any prescribing for alcohol use disorder right now is off-label. Insurance coverage on that basis is inconsistent. People are increasingly self-paying — including through compounded versions that have their own quality and safety questions.

Adherence and long-term effects matter. GLP-1 medications come with side effects: nausea, GI symptoms, gallbladder disease in some patients, and emerging questions about muscle-mass loss with extended use. They also typically require ongoing weekly injection. Forcing a patient to choose between sobriety and tolerable side effects is the wrong framing — and that’s the work that’s still ahead of the field.

This is not a substitute for the social, behavioral, and recovery-community work that gets people through alcohol use disorder. The trial paired the medication with weekly cognitive behavioral therapy. The CBT did most of the placebo arm’s 27.4% reduction. The story here is adjunct, not replacement.

What to do with this news if you’re considering it

If you have alcohol use disorder and are reading this article: the most important thing the trial says is that evidence-based medications for AUD work, that better ones may be coming, and that pairing medication with structured behavioral support outperforms either alone. That has been true for naltrexone and acamprosate for years, and it remains true here.

A reasonable conversation with a clinician right now might cover: whether you have a co-occurring indication for which semaglutide is approved (diabetes, obesity); what existing evidence-based medications you’ve tried; whether your insurance will cover any of the above; and what behavioral or recovery-community supports you have in place. Those four pieces matter more than the trial headline.

If you’re considering compounded semaglutide from telehealth providers, ask: who is the prescriber, what is the compounding pharmacy, and what is the dosing schedule. The compounded GLP-1 market has had quality issues over the past two years, and a vial that’s $300 cheaper isn’t a bargain if it isn’t what the label says.

If you’re considering compounded semaglutide from telehealth providers, ask: who is the prescriber, what is the compounding pharmacy, and what is the dosing schedule.

Why this matters for people in recovery

Three things are worth holding together.

The first is hope: a generation of researchers has watched alcohol use disorder be under-treated, under-medicated, and culturally framed as a willpower problem. The GLP-1 data, alongside extended-release naltrexone and other recent work, are part of a slow correction. Alcohol use disorder is a medical condition, and we are getting better medications for it.

The second is honest skepticism: one trial doesn’t change practice. Two trials and a meta-analysis change the conversation. Phase 3 changes practice.

The third is the equity question: GLP-1 medications are expensive, in shortage, and inconsistently covered. If they prove out for alcohol use disorder, the field’s job is to make sure access doesn’t track only with employer insurance and BMI. The same crisis that produced 105,000 alcohol-induced deaths a year is not concentrated among well-insured people.

If you or someone you love is navigating alcohol use, you don’t have to wait for the next trial to find help. Evidence-based care exists today. The Rize platform connects you with treatment options matched to your situation, your insurance, and your goals — including providers who prescribe FDA-approved medications for alcohol use disorder.

Find treatment matched to your situation →

If you are in immediate crisis or thinking of harming yourself, call or text 988 for the Suicide & Crisis Lifeline.